Knockdown of ACAT-1 reduces amyloidogenic processing of APP

FEBS Lett. 2007 Apr 17;581(8):1688-92. doi: 10.1016/j.febslet.2007.03.056. Epub 2007 Mar 30.

Abstract

Previous studies have shown that acyl-coenzyme A:cholesterol acyl transferase (ACAT), an enzyme that controls cellular equilibrium between free cholesterol and cholesteryl esters, modulates proteolytic processing of APP in cell-based and animal models of Alzheimer's disease. Here we report that ACAT-1 RNAi reduced cellular ACAT-1 protein by approximately 50% and cholesteryl ester levels by 22% while causing a slight increase in the free cholesterol content of ER membranes. This correlated with reduced proteolytic processing of APP and 40% decrease in Abeta secretion. These data show that even a modest decrease in ACAT activity can have robust suppressive effects on Abeta generation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Amyloid beta-Peptides / metabolism*
  • Cholesterol Esters / analysis
  • Cholesterol Esters / metabolism
  • Endoplasmic Reticulum / enzymology
  • Humans
  • RNA Interference
  • RNA, Small Interfering / pharmacology
  • Sterol O-Acyltransferase / antagonists & inhibitors
  • Sterol O-Acyltransferase / genetics
  • Sterol O-Acyltransferase / metabolism*

Substances

  • Amyloid beta-Peptides
  • Cholesterol Esters
  • RNA, Small Interfering
  • Sterol O-Acyltransferase
  • sterol O-acyltransferase 1